Suraksha's revenue grew 22.5%, but profit fell 14% in Q4.
Full-year profit grew just 1.4% as margin compression from network expansion ate into the top line.
— 5 earlier stories on Suraksha Diagnostic Ltd. →What's new
- Q4 PAT fell 14.1% despite a 24.7% revenue jump, showing margin pressure.
- Full-year PAT grew only 1.4% on 22.5% revenue growth for FY26.
- EBITDA margin compressed to 31.8% for the full year from 33.8%.
Why this matters
Suraksha is spending to grow, but the cost of adding new centres is currently outpacing the profit they generate. Revenue is scaling, but the earnings power per rupee of sales is shrinking. The results confirm the margin hit the board flagged earlier.
What we're watching
- Whether new centres begin contributing positively to margins in H1 FY27.
- If the revenue growth rate can be sustained at >20%.
- Management's commentary on the timeline for margin recovery.
The full read
Suraksha Diagnostic grew revenue by 22.5% for FY26, but the profit needle barely moved. PAT increased just 1.4% for the year, and actually fell 14.1% in Q4. The problem is clear: EBITDA margins slipped to 31.8% from 33.8% as the chain expanded its network. The spending is for growth, but it's currently more expensive than the revenue it brings in. This is a classic expansion squeeze. The press release itself is routine, rehashing numbers from the board meeting, but it confirms the operational profile: top-line momentum is strong, but the earnings quality is deteriorating in the short term. The open question is when these new centres start paying their way.
Questions answered
- Why did Suraksha's profit fall even as revenue surged?
- New diagnostic centre launches increased operating costs, compressing EBITDA margins for the full year. This cost expansion outpaced the revenue gains, leading to flat full-year profit growth.
- How significant was the Q4 profit decline?
- Q4 PAT fell 14.1% year-on-year despite a 24.7% jump in total income for the quarter. This indicates the margin pressure intensified in the final three months.
- Are these results a surprise?
- No. The audited numbers were previously disclosed in the board meeting outcome, making this press release a formal public communication. There is no new information.
- What does the margin compression mean for investors?
- It means the company is currently sacrificing near-term profitability to invest in its network. The open question is whether the new centres will drive enough incremental revenue to restore margins over time.
Suraksha Diagnostic Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on SURAKSHA →- 21 May 2026 · 9:04 PM IST Suraksha's revenue grew 22.5%, but profit fell 14% in Q4.
- 40d ago Suraksha Diagnostic transcript confirms previously issued FY27 guidance
- 45d ago Suraksha Diagnostic cools growth targets to 15% for FY27
- 46d ago Suraksha Diagnostic revenue lifts 21% as margins tighten
- 46d ago Suraksha Diagnostic's revenue grows 20%. Profit doesn't follow.